Safety and Preliminary Efficacy of ALT001 in MSA-C

Phase 1, randomised, open-label trial of ALT001 in multiple system atrophy (MSA) (2 arms). Primary endpoints: Incidence of adverse events and serious adverse events at 90 days and Changes in clinical laboratory test parameters, vital signs, neurological examination abnormalities and ECG abnormalities at 90 days. Started Jun 2026; status: recruiting.